Back
Directs Sun Pharma to Seek Before Launching Semaglutide Tablets
In a significant development for pharmaceutical patent litigation, the has declined to grant an in a filed by Danish drugmaker against . However, the court imposed a crucial procedural safeguard: Sun Pharma cannot commercially manufacture or launch its proposed Semaglutide tablets without first obtaining from the court. The order, delivered by Justice Anup Jairam Bhambhani on , balances the competing interests of patent protection and market access while leaving contested legal questions unresolved.
Background: A Clash Over GLP-1 Drug Patents
The dispute centers on Semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss drugs. Novo Nordisk holds a patent covering Semaglutide as well as formulations containing the absorption enhancer salt of N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC). Sun Pharma, one of India’s largest pharmaceutical companies, has developed generic versions of Semaglutide tablets in 3 mg, 7 mg, and 14 mg dosages, and completed clinical trials. At a meeting on , the —a government advisory body—recommended granting Sun Pharma permission to manufacture and market these tablets.
Novo Nordisk promptly approached the , alleging that Sun Pharma’s product would infringe its patent, particularly claim(s) covering the combination of Semaglutide with SNAC. The plaintiff relied on the SEC’s recommendation as evidence that Sun Pharma was on the verge of entering the market.
The Court’s Directive: Mandate
While Justice Bhambhani did not find it appropriate to issue an at this stage, he imposed an affirmative obligation on Sun Pharma to seek the court’s nod before taking any commercial steps. The operative part of the order states:
“As and when a manufacturing license is granted to the defendant for the manufacture of Semaglutide Tablets, before taking any steps towards commercial manufacturing or launch of the said product, the defendant shall move an appropriate application before this court seeking for that purpose.”
This directive effectively creates a that prevents Sun Pharma from rushing to market while the patent issues remain unresolved. The court clarified that it will consider Novo Nordisk’s plea for after Sun Pharma files such an application.
A Preliminary Hurdle:
Sun Pharma raised a preliminary objection challenging the maintainability of the suit itself. , appearing for Sun Pharma, argued that the lacked because neither party is based in Delhi. She further submitted that the suit was premature, as Sun Pharma had not yet applied for a commercial manufacturing license—a process that would take considerable time.
Justice Bhambhani, however, declined to rule on the jurisdictional challenge at this stage, leaving the objection open for adjudication at a later date. This approach is common in patent cases where urgency demands interim measures before jurisdictional issues are fully resolved.
The Ambiguity at the Heart of the Case
A key factor in the court’s decision to withhold an was the ambiguity surrounding the exact composition of Sun Pharma’s product. The judge noted:
“It appears there is ambiguity as to the defendant's stand, in particular as to whether their pharmaceutical product contains Salt of NAC alongwith Semaglutide; and if so, in what proportion/range; and whether the quantity of SNAC contained in the defendant's product maps onto the plaintiffs' patent claim(s).”
This uncertainty made it impossible for the court to assess the likelihood of infringement—a necessary element for granting an . Without clarity on whether Sun Pharma’s tablets actually incorporate SNAC at levels covered by the patent, the court could not find a in Novo Nordisk’s favor.
, representing Novo Nordisk, had submitted supporting documents to demonstrate Sun Pharma’s imminent launch, but the court found the evidentiary record insufficient for a final decision on an injunction.
Legal Analysis: Balancing Patent Rights and Market Access
The ’s order reflects a pragmatic approach in complex pharmaceutical patent disputes. By requiring , the court ensures that no irreversible market entry occurs while the patent claims are still being evaluated. This —more flexible than a —allows the court to revisit the matter when Sun Pharma actually seeks a manufacturing license.
The rejection of Sun Pharma’s jurisdictional objection for now is also noteworthy. Courts often adopt a “wait and watch” approach in patent suits where delay could cause . If the court later determines it lacks jurisdiction, the entire suit could be dismissed, but in the interim, the protective order remains in place.
The ambiguity over SNAC content is a classic issue in pharmaceutical patent litigation: generic manufacturers may attempt to design around a patent by using different excipients or ratios. Novo Nordisk will need to present precise evidence—likely through reverse engineering or product samples—to show that Sun Pharma’s tablets fall within the patent claims. Conversely, Sun Pharma may argue that its formulation is distinct and non-infringing.
Implications for Pharmaceutical Patent Litigation
This case highlights the strategic importance of procedural timing. Sun Pharma’s argument that the suit is premature because it has not yet applied for a manufacturing license underscores the tension between patent holders seeking to preempt market entry and generic companies waiting for regulatory approvals.
The order also demonstrates that courts are willing to impose interim compliance obligations without granting full injunctions, thereby preserving the . For patentees, the lesson is that early evidence of infringement must be concrete; mere allegations based on regulatory recommendations may not suffice for an injunction.
For generic applicants, the ruling serves as a reminder that even without a granted license, they remain subject to court oversight if a patent challenge is pending. Any attempt to launch commercial quantities could invite .
Conclusion
The has charted a middle path in the Novo Nordisk–Sun Pharma dispute. By declining an but requiring prior court approval before launch, Justice Bhambhani has maintained judicial control over the process while giving both parties an opportunity to present their evidence more fully. The jurisdictional question and the infringement analysis will be taken up later, likely after Sun Pharma obtains its manufacturing license. The matter is next listed before the Joint Registrar on , setting the stage for further legal battles over one of the most lucrative drug patents in recent years.
Legal professionals should watch this case closely for its treatment of in patent suits and the evolving standards for in pharmaceutical matters. The balance between innovation incentives and affordable access to medicines will continue to be tested in courtrooms across India.
